B-cells and Humoral Immunity in Multiple Sclerosis. Implications for Therapy

Overview

Journal Immunol Res

Specialty Allergy & Immunology

Date 2007 Oct 26

PMID 17960498

Citations 6

Authors

Sangjin Oh

Cornelia Cudrici

Takahiro Ito

Horea Rus

Affiliations

Soon will be listed here.

Abstract

B-cells and humoral immunity have been implicated in the pathogenesis of multiple sclerosis. The most common pattern of demyelinating pathology in multiple sclerosis is associated with the deposition of antibodies and the activation of complement, as well as T-cells and macrophages. Plasmapheresis has been found to be an efficient therapeutic approach in patients with this type of pathological lesion. Recent data have indicated that autoantibodies and complement C5b-9 may be involved in lesion formation and might also be beneficial for lesion repair. Thus, the role played by B-cells and humoral immunity is rather complex, and new strategies for targeting B-cell responses are continuing to emerge.

Citing Articles

Soluble Antigen Arrays for Selective Desensitization of Insulin-Reactive B Cells.

Leon M, Wemlinger S, Larson N, Ruffalo J, Sestak J, Middaugh C Mol Pharm. 2019; 16(4):1563-1572.

PMID: 30681867 PMC: 7446942. DOI: 10.1021/acs.molpharmaceut.8b01250.

Multivalent Soluble Antigen Arrays Exhibit High Avidity Binding and Modulation of B Cell Receptor-Mediated Signaling to Drive Efficacy against Experimental Autoimmune Encephalomyelitis.

Hartwell B, Pickens C, Leon M, Berkland C Biomacromolecules. 2017; 18(6):1893-1907.

PMID: 28474886 PMC: 7388272. DOI: 10.1021/acs.biomac.7b00335.

Current understanding on the role of standard and immunoproteasomes in inflammatory/immunological pathways of multiple sclerosis.

Bellavista E, Santoro A, Galimberti D, Comi C, Luciani F, Mishto M Autoimmune Dis. 2014; 2014:739705.

PMID: 24523959 PMC: 3910067. DOI: 10.1155/2014/739705.

Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis.

Crespo O, Kang S, Daneman R, Lindstrom T, Ho P, Sobel R J Clin Immunol. 2011; 31(6):1010-20.

PMID: 21847523 PMC: 3225802. DOI: 10.1007/s10875-011-9579-6.

Structural basis for inhibition of complement C5 by the SSL7 protein from Staphylococcus aureus.

Laursen N, Gordon N, Hermans S, Lorenz N, Jackson N, Wines B Proc Natl Acad Sci U S A. 2010; 107(8):3681-6.

PMID: 20133685 PMC: 2840425. DOI: 10.1073/pnas.0910565107.

References

Wucherpfennig K, Catz I, Hausmann S, Strominger J, Steinman L, Warren K . Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes. J Clin Invest. 1997; 100(5):1114-22. PMC: 508286. DOI: 10.1172/JCI119622. View

Genc K, Dona D, Reder A . Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J Clin Invest. 1997; 99(11):2664-71. PMC: 508112. DOI: 10.1172/JCI119455. View

Hauser S, Dawson D, Lehrich J, Beal M, KEVY S, Propper R . Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med. 1983; 308(4):173-80. DOI: 10.1056/NEJM198301273080401. View

Fillatreau S, Sweenie C, McGeachy M, Gray D, Anderton S . B cells regulate autoimmunity by provision of IL-10. Nat Immunol. 2002; 3(10):944-50. DOI: 10.1038/ni833. View

Tourtellotte W, Walsh M, Baumhefner R, Staugaitis S, Shapshak P . The current status of multiple sclerosis intra-blood-brain-barrier IgG synthesis. Ann N Y Acad Sci. 1984; 436:52-67. DOI: 10.1111/j.1749-6632.1984.tb14775.x. View

Cross A, Stark J, Lauber J, Ramsbottom M, Lyons J . Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 2006; 180(1-2):63-70. PMC: 1769354. DOI: 10.1016/j.jneuroim.2006.06.029. View

Cepok S, Rosche B, Grummel V, Vogel F, Zhou D, Sayn J . Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain. 2005; 128(Pt 7):1667-76. DOI: 10.1093/brain/awh486. View

Weiner H, Dau P, Birnbaum G, FELDSTEIN M, Khatri B, Petajan J . Plasma exchange in acute multiple sclerosis. Design of a cooperative study. Arch Neurol. 1983; 40(11):691-2. DOI: 10.1001/archneur.1983.04050100031010. View

Giulino L, Bussel J, Neufeld E . Treatment with rituximab in benign and malignant hematologic disorders in children. J Pediatr. 2007; 150(4):338-44, 344.e1. PMC: 2586083. DOI: 10.1016/j.jpeds.2006.12.038. View

10.

Prineas J . Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord. Science. 1979; 203(4385):1123-5. DOI: 10.1126/science.424741. View

11.

Walsh M, Tourtellotte W . Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis. J Exp Med. 1986; 163(1):41-53. PMC: 2188010. DOI: 10.1084/jem.163.1.41. View

12.

Storch M, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann H . Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol. 1998; 43(4):465-71. DOI: 10.1002/ana.410430409. View

13.

Sellebjerg F, Jaliashvili I, Christiansen M, Garred P . Intrathecal activation of the complement system and disability in multiple sclerosis. J Neurol Sci. 1998; 157(2):168-74. DOI: 10.1016/s0022-510x(98)00086-0. View

14.

Monson N, Cravens P, Frohman E, Hawker K, Racke M . Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol. 2005; 62(2):258-64. DOI: 10.1001/archneur.62.2.258. View

15.

Paolino E, Fainardi E, Ruppi P, Tola M, Govoni V, Casetta I . A prospective study on the predictive value of CSF oligoclonal bands and MRI in acute isolated neurological syndromes for subsequent progression to multiple sclerosis. J Neurol Neurosurg Psychiatry. 1996; 60(5):572-5. PMC: 486374. DOI: 10.1136/jnnp.60.5.572. View

16.

Seamons A, Perchellet A, Goverman J . Endogenous myelin basic protein is presented in the periphery by both dendritic cells and resting B cells with different functional consequences. J Immunol. 2006; 177(4):2097-106. DOI: 10.4049/jimmunol.177.4.2097. View

17.

Dau P, PETAJAN J, Johnson K, Panitch H, Bornstein M . Plasmapheresis in multiple sclerosis: preliminary findings. Neurology. 1980; 30(10):1023-8. DOI: 10.1212/wnl.30.10.1023. View

18.

Ozawa K, Suchanek G, Breitschopf H, Bruck W, Budka H, Jellinger K . Patterns of oligodendroglia pathology in multiple sclerosis. Brain. 1994; 117 ( Pt 6):1311-22. DOI: 10.1093/brain/117.6.1311. View

19.

Koski C, Estep A, Shin M, Highbarger L, Hansch G . Complement regulatory molecules on human myelin and glial cells: differential expression affects the deposition of activated complement proteins. J Neurochem. 1996; 66(1):303-12. DOI: 10.1046/j.1471-4159.1996.66010303.x. View

20.

Grewal I, Foellmer H, Grewal K, Xu J, Hardardottir F, Baron J . Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science. 1996; 273(5283):1864-7. DOI: 10.1126/science.273.5283.1864. View